Transenterix (NYSEAMERICAN: TRXC) and Baxter International (NYSE:BAX) are both medical equipment, supplies & distribution – nec companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.


Baxter International pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. Transenterix does not pay a dividend. Baxter International pays out 34.4% of its earnings in the form of a dividend.

Insider & Institutional Ownership

82.9% of Baxter International shares are held by institutional investors. 0.1% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares Transenterix and Baxter International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Transenterix -928.85% -49.16% -33.51%
Baxter International 9.88% 15.00% 8.12%

Earnings & Valuation

This table compares Transenterix and Baxter International’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Transenterix N/A N/A N/A ($0.62) -4.65
Baxter International $10.16 billion 3.43 $4.97 billion $1.86 34.43

Baxter International has higher revenue and earnings than Transenterix. Transenterix is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Transenterix and Baxter International, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Transenterix 0 1 2 0 2.67
Baxter International 0 5 5 1 2.64

Transenterix presently has a consensus target price of $3.23, indicating a potential upside of 12.27%. Baxter International has a consensus target price of $67.00, indicating a potential upside of 4.62%. Given Transenterix’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Transenterix is more favorable than Baxter International.

Risk and Volatility

Transenterix has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.


Baxter International beats Transenterix on 10 of the 14 factors compared between the two stocks.

About Transenterix

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

About Baxter International

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.